NCCN Guidelines insights: Bladder cancer, version 2.2016: Featured updates to the NCCN Guidelines Journal Article
| Authors: | Clark, P. E.; Spiess, P. E.; Agarwal, N.; Bangs, R.; Boorjian, S. A.; Buyyounouski, M. K.; Efstathiou, J. A.; Flaig, T. W.; Friedlander, T.; Greenberg, R. E.; Guru, K. A.; Hahn, N.; Herr, H. W.; Hoimes, C.; Inman, B. A.; Kader, A. K.; Kibel, A. S.; Kuzel, T. M.; Lele, S. M.; Meeks, J. J.; Michalski, J.; Montgomery, J. S.; Pagliaro, L. C.; Pal, S. K.; Patterson, A.; Petrylak, D.; Plimack, E. R.; Pohar, K. S.; Porter, M. P.; Sexton, W. J.; Siefker-Radtke, A. O.; Sonpavde, G.; Tward, J.; Wile, G.; Dwyer, M. A.; Smith, C. |
| Article Title: | NCCN Guidelines insights: Bladder cancer, version 2.2016: Featured updates to the NCCN Guidelines |
| Abstract: | These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice. © National Comprehensive Cancer Network, Inc. 2016, All rights reserved. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 14 |
| Issue: | 10 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2016-10-01 |
| Start Page: | 1213 |
| End Page: | 1224 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 27697976 |
| PMCID: | PMC5379654 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 November 2016 -- Source: Scopus |
